A putative G-protein-coupled receptor, H218, is down-regulated during the retinoic acid-induced differentiation of F9 embryonal carcinoma cells.
We have previously cloned a novel guanine nucleotide-binding protein (G-protein)-coupled receptor, H218, that has sequence similarity to a lysophosphatidic acid receptor, edg2. We present here Northern analysis indicating that the H218 mRNA is expressed in undifferentiated F9 embryonal carcinoma cells. The H218 message is down-regulated and its stability is decreased during retinoic acid- and dibutyryl cAMP-induced differentiation. Treatment by various receptor-selective retinoids indicated that retinoic acid receptor beta or gamma signaling, but not retinoid X receptor activation, is required for the down-regulation of H218 mRNA. Activation of the H218 receptor may contribute to the phenotype of undifferentiated F9 embryonal carcinoma cells.
Li
Y
Y
Department of Biology, University of South Florida, Tampa 33620, USA.
MacLennan
A J
AJ
Rogers
M B
MB
D000818:Animals; D001565:Benzoates / Q000494:pharmacology; D003994:Bucladesine / Q000494:pharmacology; D018236:Carcinoma, Embryonal / Q000473:pathology*; D002454:Cell Differentiation / Q000187:drug effects; D002839:Chromans / Q000494:pharmacology; D015536:Down-Regulation / Q000187:drug effects*; D019204:GTP-Binding Proteins / Q000502:physiology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D051379:Mice; D009281:Naphthalenes / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D010641:Phenotype; D012333:RNA, Messenger / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D043562:Receptors, G-Protein-Coupled; D049312:Receptors, Lysophospholipid; D018168:Receptors, Retinoic Acid / Q000145:classification / Q000187:drug effects; D012176:Retinoids / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects*; D013764:Tetrahydronaphthalenes / Q000494:pharmacology; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D001565:Benzoates; C101407:CD 2019; C099555:CD 437; D002839:Chromans; D009281:Naphthalenes; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D049312:Receptors, Lysophospholipid; D018168:Receptors, Retinoic Acid; D012176:Retinoids; D013764:Tetrahydronaphthalenes; C068073:Am 580; C084904:Ro 41-5253; D014212:Tretinoin; D003994:Bucladesine; D019204:GTP-Binding Proteins